The nationwide recall affects specific lots of a three-ingredient prescription blood pressure medication manufactured by Macleods Pharma USA. The FDA classified the action as Class II after the tablets failed dissolution specifications. Here is what patients need to check.
The olmesartan recall is drawing attention after the US Food and Drug Administration (FDA) classified a nationwide recall involving 3,744 bottles of a prescription blood pressure medication manufactured by Macleods Pharma USA.
The affected medication combines three active ingredients: olmesartan medoxomil, amlodipine and hydrochlorothiazide. According to the FDA information cited in recent reporting, the tablets failed dissolution specifications, a pharmaceutical quality test that measures how a medicine releases its ingredients under controlled conditions.
The recall covers two specific manufacturing lots, including 3,528 bottles containing 30 tablets and another 216 bottles containing 90 tablets.
Both affected lots have an expiration date of May 31, 2027.
The FDA classified the recall as Class II on October 26, 2026, following the manufacturer’s voluntary recall initiation on October 7.
For patients, the most important detail is that this is a lot-specific recall, not a recall of every medication containing olmesartan.
People who take the combination medication should check the product name, National Drug Code (NDC) and lot number on their prescription bottles. Anyone who finds a matching product should contact their pharmacist or prescribing healthcare professional for instructions.
Patients should not independently stop prescribed blood pressure treatment because of a recall report.
Background and Context: What Is Olmesartan?
Olmesartan / Amlodipine / HCTZ Tablets
Olmesartan is a prescription medication belonging to a class of drugs called angiotensin II receptor blockers, commonly known as ARBs.
It is used to manage hypertension, or high blood pressure.
The recalled product is not olmesartan alone. It combines three medications that work through different mechanisms.
| Ingredient | Medication Class | Primary Role |
|---|---|---|
| Olmesartan medoxomil | Angiotensin II receptor blocker (ARB) | Helps relax blood vessels |
| Amlodipine | Calcium channel blocker | Helps relax blood vessels and reduce blood pressure |
| Hydrochlorothiazide | Thiazide diuretic | Helps the body eliminate excess salt and water |
Combining these ingredients allows healthcare professionals to prescribe multiple blood pressure treatments in one tablet.
The combination is used for patients whose hypertension requires more than one medication.
The FDA-approved labeling explains the individual ingredients and their roles in managing high blood pressure.
Reference: FDA drug labeling for olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets.
Why Are Combination Blood Pressure Medications Important?
High blood pressure is a major risk factor for cardiovascular complications, including stroke and heart disease.
Some patients require multiple medications to achieve adequate blood pressure control.
Combination tablets can simplify treatment by placing several active ingredients into a single prescription.
However, this also means that manufacturing quality matters.
Each active ingredient must be present at the intended strength, and the tablet must perform according to its approved quality specifications.
That is why dissolution testing is an important part of pharmaceutical quality control.
Latest Update: Details of the FDA Olmesartan Recall
High Blood Pressure Treatment – Fast Online Rx for Hypertension
The latest reporting, published November 2 and updated November 3, 2026, identifies Macleods Pharma USA as the manufacturer responsible for the affected medication.
The company initiated the recall on October 7. The FDA subsequently assigned the recall a Class II classification on October 26.
According to FOX Business, the recall remains ongoing and involves products distributed nationwide.
Which Olmesartan Medication Has Been Recalled?
The affected product is:
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets
The recall covers the following products:
| Identification | 30-count bottle | 90-count bottle |
|---|---|---|
| Manufacturer | Macleods Pharma USA | Macleods Pharma USA |
| Lot number | 12251163A | 12251163B |
| NDC | 33342-246-07 | 33342-246-10 |
| Quantity recalled | 3,528 bottles | 216 bottles |
| Expiration date | May 31, 2027 | May 31, 2027 |
Important recall identification
Check these two lot numbers on your prescription bottle.
3,744
Total bottles affected
- Lot 12251163A: 3,528 bottles
- Lot 12251163B: 216 bottles
- Expiration: May 31, 2027
The National Drug Code is another important identifier. It helps distinguish the affected products from other medicines that may contain the same active ingredients.
Patients should compare all available details rather than relying on the drug name alone.
Source: FOX Business: Thousands of Blood Pressure Medication Bottles Recalled Nationwide After Pills Fail Quality Test. Fox Business+2
Why Did the FDA Recall the Medication?
The FDA identified the reason as:
Failed dissolution specifications.
Dissolution testing measures how quickly and how completely a tablet releases its active ingredients when exposed to a specified liquid under controlled laboratory conditions.
This is an important pharmaceutical quality test because a medicine must release its ingredients in a way that meets its approved performance standards.
If a tablet fails dissolution testing, it may not release its active ingredients at the expected rate.
For a blood pressure medication, that raises concerns about whether the medicine will perform as intended.
It is important to distinguish this issue from contamination.
The available recall reporting identifies a dissolution-quality failure. It does not establish that the affected tablets were contaminated or that every bottle contained defective tablets.
The exact clinical impact on individual patients has not been established in the reporting.
What Does an FDA Class II Recall Mean?
The FDA uses different classifications to communicate the potential health risks associated with recalled products.
A Class II recall indicates that using or being exposed to the affected product may cause temporary or medically reversible adverse health consequences.
The probability of serious adverse health consequences is considered remote under the FDA’s classification.
This does not mean the recall should be ignored.
A medication that does not meet its quality specifications can create uncertainty about its expected performance.
Patients should therefore take the recall seriously and seek professional guidance about affected prescriptions.Fox Business+2
What Should Patients Do If They Have the Recalled Olmesartan Medication?
Black female pharmacist reading label on a medicine in drugstore.
The most important step is identifying whether the prescription bottle matches either recalled lot.
Patients and caregivers can follow these steps.
Step 1: Find the prescription bottle.
Locate the container labeled Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets.
Step 2: Check the lot number.
Look for either:
- 12251163A
- 12251163B
Step 3: Compare the NDC.
Check whether the bottle lists:
- 33342-246-07
- 33342-246-10
Step 4: Contact your pharmacist or prescribing healthcare professional.
If the bottle matches the recalled details, ask for guidance on replacement medication and what to do with the affected supply.
Step 5: Follow professional instructions.
Do not independently discontinue or change your prescribed blood pressure treatment.
Important health guidance
A recall does not mean patients should suddenly stop taking their prescribed blood pressure medication.
Abruptly stopping treatment can allow blood pressure to become uncontrolled.
If your medication matches a recalled lot, contact your pharmacist or prescriber promptly to discuss the appropriate next step.
If you experience severe or concerning symptoms, seek appropriate medical care.
Does the Recall Affect Every Olmesartan Prescription?
No.
The reported recall concerns two specific lots of one three-ingredient combination medication manufactured by Macleods Pharma USA.
It does not establish that:
- Every olmesartan medication has been recalled.
- All amlodipine prescriptions are affected.
- All hydrochlorothiazide products are affected.
- Every generic version of the combination medication is affected.
- Every bottle manufactured by Macleods Pharma USA is affected.
This distinction matters because different manufacturers, production batches and NDCs can identify different pharmaceutical products.
Patients should verify the exact product and lot number with their pharmacist.
Expert Analysis: Why Dissolution Testing Matters in Pharmaceutical Manufacturing
The olmesartan recall highlights an important part of pharmaceutical manufacturing that consumers rarely think about.
A medicine can contain the correct active ingredients and still fail an important quality requirement.
That is where dissolution testing becomes relevant.
1. Dissolution Is Not the Same as Disintegration
These terms are related but have different meanings.
Disintegration measures how a tablet breaks apart into smaller particles.
Dissolution measures how the active ingredient moves into a liquid solution.
A tablet may break apart but still fail to release its ingredients according to the required dissolution profile.
That distinction is important when evaluating pharmaceutical performance.
2. Why the Release Rate Matters
Oral medications must release their active ingredients so that the body can absorb them.
If the dissolution characteristics differ from the required specifications, the amount or timing of drug release may be affected.
For a combination blood pressure medicine, this creates a potential concern about whether the treatment performs as intended.
However, a failed laboratory test does not automatically prove that every patient who took a tablet experienced reduced effectiveness.
The specific clinical impact requires appropriate evaluation.
3. Why Pharmaceutical Quality Control Matters
Drug manufacturers must maintain quality standards throughout production.
These standards include:
- Raw material testing.
- Manufacturing process controls.
- Tablet uniformity.
- Stability testing.
- Dissolution testing.
- Packaging and labeling verification.
The recall demonstrates why these procedures are important even for established prescription medicines.
The FDA’s pharmaceutical guidance and drug-quality framework provide additional context on manufacturing standards and product performance.
Broader Implications: What the Olmesartan Recall Means for the Pharmaceutical Industry
The recall raises several important questions about pharmaceutical quality, patient safety and the role of regulatory oversight.
1. Greater Attention to Generic Drug Quality
Generic medications play an important role in making prescription treatments more accessible.
They must meet applicable quality and regulatory requirements.
A recall involving a generic combination medication does not establish a problem with generic drugs as a category.
However, it highlights why manufacturing oversight and batch-level quality testing remain essential.
2. Better Communication Between Manufacturers and Pharmacies
When a medication is recalled, patients need accurate information quickly.
Manufacturers, distributors, pharmacies and healthcare professionals all have roles in communicating recall notices.
Clear lot identification helps pharmacists determine whether a patient’s prescription is affected.
3. Patient Awareness of Prescription Details
Many people recognize their medication by its brand or generic name.
But recalls frequently involve specific lots rather than every product carrying the same name.
Knowing where to find a lot number and NDC can make it easier to respond to a recall.
4. The Importance of FDA Oversight
The FDA’s recall classification system provides a way to communicate the potential health implications of product-quality problems.
It also helps patients and healthcare professionals distinguish between different levels of recall risk.
The Macleods recall reinforces the importance of monitoring pharmaceutical quality after products have entered the distribution chain.
For additional coverage, The Tech Marketer can internally link this article to its healthcare technology and consumer safety coverage.
Related History: Other Blood Pressure Medication Recalls in 2026
The Macleods recall is not the only blood pressure medication quality issue reported this year.
In September 2026, Inventia Healthcare Ltd. initiated another recall involving chlorthalidone tablets.
According to FOX Business, the September recall covered 13,567 bottles of 25-milligram chlorthalidone tablets after the product failed dissolution testing.
The company had also recalled more than 11,000 bottles of the medication in June.
These are separate recalls involving a different medication and manufacturer.
| Recall | Manufacturer | Medication | Reported quantity |
|---|---|---|---|
| June 2026 | Inventia Healthcare | Chlorthalidone 25 mg | 11,460 bottles |
| September 2026 | Inventia Healthcare | Chlorthalidone 25 mg | 13,567 bottles |
| October 2026 | Macleods Pharma USA | Olmesartan combination tablets | 3,744 bottles |
The similarities are related to dissolution testing, but the products, companies and manufacturing lots are different.
These events should not be combined into a single recall.
Sources: FOX Business September recall coverage and FOX Business October recall coverage. Fox Business+2
What Happens Next?
The immediate priority is helping patients identify potentially affected prescriptions and obtain appropriate guidance.
Several developments are worth monitoring.
- Recall updates: Watch for additional information from the FDA and Macleods Pharma USA.
- Pharmacy notifications: Pharmacies may communicate with customers who received affected lots.
- Product replacement: Patients with matching bottles should discuss replacement arrangements with their pharmacists or prescribers.
- Quality investigations: Further information may clarify the manufacturing issue and its potential implications.
- Regulatory updates: The FDA may update its recall information as the process develops.
Patients can monitor the FDA’s official resources through its drug recall and safety information.
The key issue is whether any additional lots or products become subject to recall. The current reporting establishes the two Macleods lots listed above, not a broader recall of all olmesartan-containing medications.
Conclusion: Why Patients Should Take the Olmesartan Recall Seriously
The olmesartan recall highlights why pharmaceutical quality testing matters, particularly for medications used to manage chronic conditions such as high blood pressure.
Macleods Pharma USA’s recall involves 3,744 bottles across two manufacturing lots. The FDA classified the action as Class II after the tablets failed dissolution specifications.
For patients, the most important action is checking the prescription bottle.
The lot numbers 12251163A and 12251163B, together with their corresponding NDCs, identify the affected products.
This is not a recall of every olmesartan prescription, and patients should not independently stop their blood pressure treatment.
As more information becomes available, patients should follow updates from the FDA and consult their healthcare professionals.
Ultimately, this incident is a reminder that medication safety depends not only on the ingredients listed on a prescription label but also on whether the finished product meets the quality standards required for reliable treatment.
Frequently Asked Questions (FAQ)
1. What is the olmesartan recall about?
The olmesartan recall involves 3,744 bottles of a combination prescription medication containing olmesartan medoxomil, amlodipine and hydrochlorothiazide. The tablets failed FDA dissolution specifications.
2. Which company manufactured the recalled medication?
Macleods Pharma USA, based in New Jersey, is the manufacturer identified in the recall reporting.
3. Which olmesartan lot numbers are recalled?
The affected lot numbers are:
- 12251163A for 30-count bottles.
- 12251163B for 90-count bottles.
Both have an expiration date of May 31, 2027.
4. What are the NDC numbers for the recalled bottles?
The affected National Drug Codes are:
- 33342-246-07 for 30-count bottles.
- 33342-246-10 for 90-count bottles.
5. Why did the FDA recall the blood pressure medication?
The tablets failed dissolution specifications. This means they did not meet the required laboratory standards for releasing their active ingredients into a liquid under controlled testing conditions.
6. What does an FDA Class II recall mean?
A Class II recall means using or being exposed to the affected product may cause temporary or medically reversible health consequences. The probability of serious adverse health consequences is considered remote.
7. Should I stop taking my olmesartan medication?
Do not independently stop prescribed blood pressure medication. If your prescription matches the recalled product and lot number, contact your pharmacist or healthcare professional promptly for instructions.
8. Does the recall affect all olmesartan medications?
No. The reported recall covers two specific lots of a three-ingredient combination medication manufactured by Macleods Pharma USA. Other olmesartan products are not automatically included.
9. What is dissolution testing?
Dissolution testing measures how a tablet releases its active ingredients into a liquid under controlled laboratory conditions. It helps manufacturers evaluate whether a medicine meets its required quality specifications.
10. Where can patients check for FDA medication recalls?
Patients can visit the FDA Drug Safety and Availability website and consult their pharmacist or prescribing healthcare professional.
Sources & References
The following sources support the recall details and pharmaceutical background covered in this article.
1. FOX Business: Thousands of Blood Pressure Medication Bottles Recalled Nationwide After Pills Fail Quality Test
2. WUSA9: Blood Pressure Medication Recalled: Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide
3. WMUR: FDA Recalls Thousands of Blood Pressure Bottles, Says Pills Failed Quality Tests
4. US Food and Drug Administration: Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Drug Label
5. US Food and Drug Administration: Drug Safety and Availability
6. FOX Business: Widely Used Blood Pressure Medication Recalled Nationwide
